COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial
Authors
Camilleri, M.Sive, J.
Wilson, W.
Pang, G.
Jenner, R.
Phillips, Elizabeth H
Popat, R.
Ramasamy, K.
Bygrave, C.
Dadaga, T.
Streetly, M.
Cavenagh, J.
Chapman, M.
Barrington, S.
Pike, L.
Owen, R.
Clifton-Hadley, L.
Yong, K.
Affiliation
Haematology Department, University College Hospitals, London, UK.Issue Date
2020
Metadata
Show full item recordAbstract
NoneCitation
Camilleri M, Sive J, Wilson W, Pang G, Jenner R, Phillips E, et al. COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial. Br J Haematol. 2021;192(1):e14-e6.Journal
British Journal of HaematologyDOI
10.1111/bjh.17168PubMed ID
33222153Additional Links
https://dx.doi.org/10.1111/bjh.17168Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bjh.17168
Scopus Count
Collections
Related articles
- Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
- Authors: Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, Jakubowiak AJ
- Issue date: 2021 Feb 5
- Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
- Authors: Jackson GH, Pawlyn C, Cairns DA, de Tute RM, Hockaday A, Collett C, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Rocci A, Snowden JA, Jenner MW, Cook G, Russell NH, Drayson MT, Gregory WM, Kaiser MF, Owen RG, Davies FE, Morgan GJ, UK NCRI Haemato-oncology Clinical Studies Group
- Issue date: 2021 Jan
- Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
- Authors: Sheng Z, Li G, Li B, Liu Y, Wang L
- Issue date: 2017 Jun
- Retinal Pigment Epithelium Tears in a 67-Year-Old Man.
- Authors: Sultan H, Kellogg C, El-Annan J
- Issue date: 2018 May 1
- A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
- Authors: Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, Ong SY, Xu M, SGHMM1 Investigators, Chng WJ, Goh YT, Nagarajan C
- Issue date: 2021 Sep 3